Implantica AG, a Swiss-based medtech company, has received positive feedback from the US FDA on its RefluxStop device, bringing it closer to securing US market approval for its treatment of acid reflux disease affecting an estimated 1 billion people…

Implantica AG, a Swiss-based implant manufacturer, has received positive feedback from the US FDA on its RefluxStop device, a minimally invasive implant designed to alleviate symptoms of acid reflux, paving the way for potential US market launch.

Implantica AG, a Swiss-based medical technology company, has navigated significant market fluctuations, with its stock price ranging from 22 to 83 SEK, as it continues to advance its mission of enhancing healthcare through innovative medical implant…

Implantica AG has reported a net loss and decreased sales, but strategic moves such as completing a FDA PMA submission and developing new production tools position the company for future growth and success.

Implantica AG, a Swiss-based medical implant and instrument leader, has demonstrated significant growth and market confidence, driven by its commitment to innovation and excellence in medical technology.

Implantica AG has submitted the final module for FDA approval of its RefluxStop device, a treatment for acid reflux that could significantly enhance the company’s market presence and financial performance.

Implantica AG’s RefluxStop, a medical implant for gastroesophageal reflux disease, gained significant attention at the Digestive Disease Week conference in the US, highlighting its potential impact in the American market.

Implantica AG’s RefluxStop procedure generated significant interest at the Digestive Disease Week conference, highlighting the company’s potential to make a significant impact in the U.S. medical implant market.

Implantica AG’s RefluxStop, a medical device for treating digestive diseases, is generating significant buzz and potential for market disruption, but faces regulatory challenges and market uncertainties.

Implantica AG’s RefluxStop product generated significant interest from US surgeons at the Digestive Disease Week conference, pending FDA approval.